Therefore, our data suggested that AID is a poor prognostic marker of High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, as it has a different pathological background. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.